Berlin, Germany

Daniel Korr

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 10.7

ph-index = 2

Forward Citations = 48(Granted Patents)


Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):

Title: The Innovative Contributions of Daniel Korr

Introduction

Daniel Korr is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of hyperproliferative diseases. With a total of five patents to his name, Korr's work has the potential to impact cancer treatment and other related disorders.

Latest Patents

Among his latest patents, Korr has developed 4H-pyrrolo[3,2-c]pyridin-4-one derivatives. These compounds are designed for use in the treatment or prophylaxis of diseases, specifically targeting hyperproliferative diseases and disorders responsive to the induction of cell death. This includes haematological tumours, solid tumours, and metastases that harbor a mutant EGFR with exon 19 or 21 mutations. Additionally, he has created acyl sulfonamides for treating cancer, providing new avenues for pharmaceutical applications.

Career Highlights

Throughout his career, Korr has worked with notable companies such as Bayer Aktiengesellschaft and The Broad Institute, Inc. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Korr has collaborated with esteemed colleagues, including Knut Eis and Ulf Bömer. These partnerships have fostered an environment of innovation and have led to the development of impactful inventions.

Conclusion

Daniel Korr's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for advancements in cancer treatment and related medical fields.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…